• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

New evidence: It’s not necessary to fast before complete cholesterol test

Bioengineer by Bioengineer
May 28, 2019
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Study compares nonfasting lipid levels and fasting lipid levels in the same individuals, finding similar association with cardiovascular events even among those on statins

A new study adds to the growing body of evidence that it is unnecessary for most patients to fast before having bloodwork done to measure lipid levels to determine risk of future cardiovascular events. Since the 1970s, studies have suggested that fasting and nonfasting before a complete cholesterol test, otherwise known as lipid level testing, may make little difference in assessing who is at risk for a future heart attack, stroke or other cardiovascular event. But most of these studies were conducted by comparing groups of people at a population level rather than in the same individuals. This left a lingering question about how well nonfasting lipid levels can predict future events for patients. A large study led by investigators at Brigham and Women’s Hospital, Harvard Medical School, and Imperial College provides robust evidence that nonfasting lipid levels were similar to fasting lipid levels in the same individuals, predicting cardiovascular risk just as well. The results are published in JAMA Internal Medicine.

“We hope this study will be the final nail in the coffin, providing strong evidence that, within the same person, fasting or not before a lipid level test doesn’t matter for predicting cardiovascular risk,” said corresponding author Samia Mora, MD, MHS, a cardiovascular medicine specialist and director of the Center for Lipid Metabolomics in the Divisions of Preventive and Cardiovascular Medicine at the Brigham and an associate professor at Harvard Medical School. “This should reassure health care providers and patients that it doesn’t make a difference if you fast or don’t fast if the goal is to predict your cardiovascular risk.”

To conduct their study, Mora and colleagues conducted a post hoc prospective follow-up study of participants from the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA), a randomized clinical trial. Fasting and nonfasting lipid levels for more than 8,000 participants were measured four weeks apart with no intervention in between. Patients were followed for a median of 3.3 years for major coronary events (heart attacks, fatal coronary heart disease) and atherosclerotic cardiovascular disease (heart attacks, stroke, and related deaths).

The team found that risk associations of nonfasting lipid levels with coronary events were similar to those for fasting lipid levels measured four weeks later. When patients were not fasting, they had modestly higher triglyceride levels but similar cholesterol levels compared to when they were fasting.

“We spend most of our lives in a nonfasting state. And for some patients, especially those who are elderly or have diabetes, it can be risky to fast before lipid testing,” said Mora. “Health care providers held back because of concerns of variability within individuals, but the data here is so convincing. It should allow people to feel more comfortable with nonfasting lipid testing for cardiovascular risk assessment, including when taking a statin.”

Mora and colleagues note some important limitations to the study. ASCOT-LLA involved European participants, and while they represent multiple European countries, the majority were white and male. The researchers expect that the findings will be relevant to more diverse populations but note that future research should assess potential ethnic and/or racial differences.

###

This study was supported by an investigator-initiated institutional research grant from Pfizer, the National, Heart, Lung and Blood Institutes of Health (K24HL136852, R01HL134811, and HL117861), National Institutes of Health (Senior Investigator Award), and a Biomedical Research Centre Award to Imperial College from the Healthcare National Health Service Trust. The ASCOT trial was financially supported by Pfizer. Mora and co-authors report receiving personal fees and grants from Pfizer, Amgen, and Quest Diagnostics, and Atherotech Diagnostics Lab.

Paper cited: Mora, S et al. “Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm” JAMA Internal Medicine DOI: 0.1001/jamainternmed.2019.0392

Media Contact
Mark Murphy
mmurphy90@bwh.harvard.edu

Tags: CardiologyCholesterolMedicine/HealthMetabolism/Metabolic Diseases
Share13Tweet7Share2ShareShareShare1

Related Posts

EBV Integrates Non-Randomly Near Host Genes in Cartilage-Hair Hypoplasia Lymphomas

EBV Integrates Non-Randomly Near Host Genes in Cartilage-Hair Hypoplasia Lymphomas

November 18, 2026
Echocardiography Review Details Sex-Specific Cardiac Metrics and Heart Disease Risks in Women

Echocardiography Review Details Sex-Specific Cardiac Metrics and Heart Disease Risks in Women

November 18, 2026

Instructor-Led Life Support Training Equalizes Resuscitation Knowledge Across Diverse Backgrounds

November 18, 2026

Adding Leg Wrapping to Norepinephrine Infusion Curbs Post-Spinal Cesarean Hypotension

November 18, 2026
Please login to join discussion

POPULAR NEWS

  • Nurse-Led Interventions Ease Cancer Distress but Personalization Trials Are Needed

    Nurse-Led Interventions Ease Cancer Distress but Personalization Trials Are Needed

    29 shares
    Share 12 Tweet 7
  • Analysis of 1.2 Million Patients Finds 7.6 Percent Surgical Complication Rate

    29 shares
    Share 12 Tweet 7
  • Alcohol Weakens Anti-PD-1 Cancer Immunotherapy in Mice, Study Finds

    29 shares
    Share 12 Tweet 7
  • Presurgical Axitinib and Immunotherapy Linked to Shorter Kidney Cancer Thrombus Surgery

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

EBV Integrates Non-Randomly Near Host Genes in Cartilage-Hair Hypoplasia Lymphomas

Echocardiography Review Details Sex-Specific Cardiac Metrics and Heart Disease Risks in Women

Federated Deep Learning Framework Secures Connected Devices Against Multi-Vector Cyber Attacks

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.